Business Context and Reporting Period
This Form 8-K Current Report, dated January 19, 2026, covers events occurring on January 20, 2026, for Acadia Healthcare Company, Inc. (NASDAQ: ACHC). The filing primarily addresses a significant leadership transition involving the departure of the Chief Executive Officer (CEO) and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and governance changes.
Material Changes
- CEO Departure: Christopher H. Hunter departed as CEO and resigned from the Board of Directors, effective January 20, 2026. A separation and release agreement is expected but terms are not yet disclosed in this filing.
- CEO Appointment: Debra K. Osteen was appointed CEO and Class I Director, effective January 20, 2026. Ms. Osteen previously served as CEO from 2018 to 2022.
Guidance, Outlook, and Management Commentary
The filing details the compensatory arrangements for the new CEO, Debra K. Osteen, under an employment agreement dated January 19, 2026:
- Base Salary: $1,061,000 annualized.
- Cash Bonus: Target of 125% of base salary, with a maximum of 200% of the target, subject to performance criteria.
- Equity Award: An initial grant of 1,125,000 non-qualified stock options at the closing share price on the transition date.
- Vesting Schedule:
- Tranche 1 (750,000 shares): Performance-based vesting tied to Volume Weighted Average Price (VWAP) milestones of $25.00, $35.00, and $45.00.
- Tranche 2 (375,000 shares): Hybrid vesting tied to the same VWAP milestones but also requiring time-based retention until January 20, 2027.
- Severance: In the event of termination without cause or resignation for good reason, Ms. Osteen is eligible for a prorated annual bonus and 18 months of health/dental insurance premiums.
Risks and Contingencies: The equity awards are subject to forfeiture if Ms. Osteen voluntarily terminates without good reason prior to January 20, 2027, is terminated for cause, or violates restrictive covenants.
Investor Verification Checklist
- Verify the terms of the separation agreement for Christopher H. Hunter, which are expected to be disclosed in a subsequent Form 8-K.
- Confirm the current stock price relative to the $25.00, $35.00, and $45.00 VWAP milestones required for Ms. Osteen's equity vesting.
- Review the full text of the Osteen Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Monitor the press release (Exhibit 99.1) for additional strategic commentary regarding the leadership transition.